Regeneron Pharmaceuticals (REGN) Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $22.7 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 13.45% year-over-year to $22.7 billion in Q1 2026; TTM through Mar 2026 was $88.7 billion, a 19.63% increase from a year earlier, with the FY2025 full-year figure at $22.5 billion, up 18.0% from the prior year.
• Non-Current Assets rose to $22.7 billion in Q1 2026 per REGN's latest filing, from $22.5 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $22.7 billion in Q1 2026 and bottomed at $11.7 billion in Q2 2022.
• The 5-year median for Non-Current Assets is $15.5 billion (2024), against an average of $16.6 billion.
• Across the five-year window, Non-Current Assets soared 56.05% in 2022 and increased 2.03% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $13.3 billion in 2022, then advanced by 2.03% to $13.6 billion in 2023, then soared by 40.42% to $19.1 billion in 2024, then advanced by 18.0% to $22.5 billion in 2025, then gained by 0.54% to $22.7 billion in 2026.
• Per Business Quant, the three latest REGN Non-Current Assets figures stand at $22.7 billion (Q1 2026), $22.5 billion (Q4 2025), and $22.2 billion (Q3 2025).